Featured Reports, News & Insights
ICER Publishes First Annual Assessment of Barriers to Fair Access Within US Commercial Insurance Prescription Drug Coverage
Scope of assessment limited by gaps in availability of payer policies and inability to evaluate how policies are implemented, highlighting importance of improving transparency to assure fair access.
12/01/2021ICER Identifies Most Significant 2020 US Drug-Price Hikes Not Supported by New Clinical Evidence*
Out of 10 identified drugs that had substantial 2020 price increases net of rebates on top of already high current spending, seven were not supported by new clinical evidence; the net price increases on these seven drugs cost Americans an additional $1.67 billion in annual drug spend, of which nearly $1.4 billion was due to […]
11/16/2021ICER to Assess Treatments for COVID-19
Report will be subject of Midwest CEPAC meeting in April 2022; Draft Scoping Document open to public comment until September 15, 2021.
08/26/2021ICER Publishes Final Evidence Report and Policy Recommendations on Aducanumab for Alzheimer’s Disease
Independent appraisal committee unanimously determined the evidence is not adequate to demonstrate that aducanumab provides a net health benefit.
08/05/2021ICER Publishes White Paper Evaluating Policy Options to Strengthen FDA’s Accelerated Approval Pathway for Prescription Drugs
Informed by expert input from patient groups, former regulators, payers, and life science companies, white paper analyzes potential impact of a variety of reform options that address the balance between uncertainty, access, innovation, and costs.
04/26/2021ICER Analytics™ Launched to Accelerate the Real-World Application of ICER Reports, Helping Payers, the Life Science Industry, and Health Care Policy Makers Move From Insight to Action
ICER formally launched ICER Analytics™, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to develop formularies, negotiate drug prices.
11/30/2020